Skip to main content
SpringerLink
Log in
Book cover

Pathology of Lung Disease pp 611–638Cite as

Molecular Pathology of Lung Tumors

  • Chapter
  • First Online:

  • 3049 Accesses

Abstract

Within the last decade, many important discoveries were made in the regulation of growth, differentiation, apoptosis, and metastasis of lung cancers. These findings have dramatically changed the “ignorance” in the oncology community about the classification of lung carcinomas. A decade ago, oncologists were mainly interested to get the differentiation between small cell (SCLC) and non-small cell carcinomas (NSCLC) of the lung. With the findings of different responses for cisplatin and anti-angiogenic treatment in adenocarcinomas versus squamous cell carcinomas, this simple clinical lung carcinoma classification schema was abolished. Now oncologists want to know the differentiation within NSCLC, and the near future will even increase subtyping of the different NSCLC entities. In this review, we will first focus on general aspects of molecular pathology in lung carcinomas and then discuss different genetic abnormalities within the different entities. These abnormalities will be ordered according to their importance such as targeted therapy and impact on outcome.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol. 2005;32:S23–9.

    Article  CAS  PubMed  Google Scholar 

  2. Mae M, O’Connor TP, Crystal RG. Gene transfer of the vascular endothelial growth factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth. Am J Respir Cell Mol Biol. 2005;33:629–35.

    Article  CAS  PubMed  Google Scholar 

  3. Samadikuchaksaraei A, Cohen S, Isaac K, Rippon HJ, Polak JM, Bielby RC, Bishop AE. Derivation of distal airway epithelium from human embryonic stem cells. Tissue Eng. 2006;12:867–75.

    Article  CAS  PubMed  Google Scholar 

  4. Kotton DN, Fabian AJ, Mulligan RC. Failure of bone marrow to reconstitute lung epithelium. Am J Respir Cell Mol Biol. 2005;33:328–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kumar RK, Li W, O’Grady R. Maintenance of differentiated phenotype by mouse type 2 pneumocytes in serum-free primary culture. Exp Lung Res. 1995;21:79–94.

    Article  CAS  PubMed  Google Scholar 

  6. Decaussin M, Sartelet H, Robert C, Moro D, Claraz C, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol. 1999;188:369–77.

    Article  CAS  PubMed  Google Scholar 

  7. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. 2004;5 Suppl 2:S51–5.

    Article  CAS  PubMed  Google Scholar 

  8. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D. A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn. 2010;12:771–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem. 2010;285:22809–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Harris AL. Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia. 2005;7:1–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Keith RL, Miller YE, Gemmill RM, Drabkin HA, Dempsey EC, Kennedy TC, Prindiville S, Franklin WA. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res. 2000;6:1616–25.

    CAS  PubMed  Google Scholar 

  12. Takahama M, Tsutsumi M, Tsujiuchi T, Nezu K, Kushibe K, Taniguchi S, Kotake Y, Konishi Y. Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res. 1999;5:2506–10.

    CAS  PubMed  Google Scholar 

  13. Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst. 2006;98:984–95.

    Article  CAS  PubMed  Google Scholar 

  14. Maeshima AM, Tochigi N, Yoshida A, Asamura H, Tsuta K, Tsuda H. Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J Thorac Oncol. 2010;5:466–71.

    Article  PubMed  Google Scholar 

  15. Guedj N, Couvelard A, Arcangeli G, Dubois S, Thabut G, Leseche G, Fournier M, Degott C, Groussard O. Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours. Histopathology. 2004;44:251–6.

    Article  CAS  PubMed  Google Scholar 

  16. Kojima H, Shijubo N, Yamada G, Ichimiya S, Abe S, Satoh M, Sato N. Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer. 2005;104:1668–77.

    Article  CAS  PubMed  Google Scholar 

  17. Kajita T, Ohta Y, Kimura K, Tamura M, Tanaka Y, Tsunezuka Y, Oda M, Sasaki T, Watanabe G. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer. 2001;85:255–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Niki T, Iba S, Yamada T, Matsuno Y, Enholm B, Hirohashi S. Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma. J Pathol. 2001;193:450–7.

    Article  CAS  PubMed  Google Scholar 

  19. Arinaga M, Noguchi T, Takeno S, Chujo M, Miura T, Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer. 2003;97:457–64.

    Article  CAS  PubMed  Google Scholar 

  20. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H, Santiago A, Hooper AT, Bohlen P, Hicklin DJ. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med. 2002;195:1575–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res. 2003;63:8890–8.

    CAS  PubMed  Google Scholar 

  22. Lin J, Lalani AS, Harding TC, Gonzalez M, Wu WW, Luan B, Tu GH, Koprivnikar K, VanRoey MJ, He Y, Alitalo K, Jooss K. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 2005;65:6901–9.

    Article  CAS  PubMed  Google Scholar 

  23. Yano S, Muguruma H, Matsumori Y, Goto H, Nakataki E, Edakuni N, Tomimoto H, Kakiuchi S, Yamamoto A, Uehara H, Ryan A, Sone S. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin Cancer Res. 2005;11:8789–98.

    Article  CAS  PubMed  Google Scholar 

  24. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. Curr Treat Options Oncol. 2007;8:15–27.

    Article  PubMed  Google Scholar 

  25. Takahashi O, Komaki R, Smith PD, Jurgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O’Reilly MS. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012;18:1641–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Das B, Yeger H, Tsuchida R, Torkin R, Gee MF, Thorner PS, Shibuya M, Malkin D, Baruchel S. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res. 2005;65:7267–75.

    Article  CAS  PubMed  Google Scholar 

  27. Boreddy SR, Sahu RP, Srivastava SK. Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS ONE. 2011;6:e25799.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Goyal A, Poluzzi C, Willis CD, Smythies J, Shellard A, Neill T, Iozzo RV. Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1alpha and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation. J Biol Chem. 2012;287:43543–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.

    Article  CAS  PubMed  Google Scholar 

  30. Sbarbati A, Osculati F. A new fate for old cells: brush cells and related elements. J Anat. 2005;206:349–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zinner RG, Novello S, Peng G, Herbst R, Obasaju C, Scagliotti G. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer. 2010;11:126–31.

    Article  CAS  PubMed  Google Scholar 

  32. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol. 2008;73:1290–300.

    Article  CAS  PubMed  Google Scholar 

  33. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res. 2009;69:5467–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Imada K, Leonard WJ. The jak-STAT pathway. Mol Immunol. 2000;37:1–11.

    Article  CAS  PubMed  Google Scholar 

  35. Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem. 2002;277:14408–16.

    Article  CAS  PubMed  Google Scholar 

  36. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 2002;7:d376–89.

    Article  CAS  PubMed  Google Scholar 

  37. McBride KM, Reich NC. The ins and outs of STAT1 nuclear transport. Sci STKE. 2003;2003:RE13.

    PubMed  Google Scholar 

  38. Rajadurai CV, Havrylov S, Zaoui K, Vaillancourt R, Stuible M, Naujokas M, Zuo D, Tremblay ML, Park M. Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci. 2012;125:2940–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Mitola S, Brenchio B, Piccinini M, Tertoolen L, Zammataro L, Breier G, Rinaudo MT, den Hertog J, Arese M, Bussolino F. Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. Circ Res. 2006;98:45–54.

    Article  CAS  PubMed  Google Scholar 

  40. Heath CM, Stahl PD, Barbieri MA. Lipid kinases play crucial and multiple roles in membrane trafficking and signaling. Histol Histopathol. 2003;18:989–98.

    CAS  PubMed  Google Scholar 

  41. Kim J, Ahn S, Guo R, Daaka Y. Regulation of epidermal growth factor receptor internalization by G protein-coupled receptors. Biochemistry. 2003;42:2887–94.

    Article  CAS  PubMed  Google Scholar 

  42. Nomura M, Shigematsu H, Li L, Suzuki M, Takahashi T, Estess P, Siegelman M, Feng Z, Kato H, Marchetti A, Shay JW, Spitz MR, Wistuba II, Minna JD, Gazdar AF. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med. 2007;4:e125.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479–87.

    Article  CAS  PubMed  Google Scholar 

  44. Palmer RH, Vernersson E, Grabbe C, Hallberg B. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009;420:345–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Wong DW, Leung EL, Wong SK, Tin VP, Sihoe AD, Cheng LC, Au JS, Chung LP, Wong MP. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer. 2011;117:2709–18.

    Article  CAS  PubMed  Google Scholar 

  46. Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.

    Article  CAS  PubMed  Google Scholar 

  47. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39:673–7.

    Article  CAS  PubMed  Google Scholar 

  48. Raponi M, Dossey L, Jatkoe T, Wu X, Chen G, Fan H, Beer DG. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69:5776–83.

    Article  CAS  PubMed  Google Scholar 

  49. Bourdon J-C, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005;19:2122–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–6.

    Article  CAS  PubMed  Google Scholar 

  51. Husgafvel-Pursiainen K, Boffetta P, Kannio A, Nyberg F, Pershagen G, Mukeria A, Constantinescu V, Fortes C, Benhamou S. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res. 2000;60:2906–11.

    CAS  PubMed  Google Scholar 

  52. Rodin SN, Rodin AS. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A. 2000;97:12244–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 2001;61:1309–13.

    CAS  PubMed  Google Scholar 

  54. Zienolddiny S, Ryberg D, Arab MO, Skaug V, Haugen A. Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer. 2001;84:226–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Ahrendt SA, Chow JT, Yang SC, Wu L, Zhang MJ, Jen J, Sidransky D. Alcohol consumption and cigarette smoking increase the frequency of p53 mutations in non-small cell lung cancer. Cancer Res. 2000;60:3155–9.

    CAS  PubMed  Google Scholar 

  56. Hashimoto T, Tokuchi Y, Hayashi M, Kobayashi Y, Nishida K, Hayashi S, Ishikawa Y, Nakagawa K, Hayashi J, Tsuchiya E. Different subtypes of human lung adenocarcinoma caused by different etiological factors. Evidence from p53 mutational spectra. Am J Pathol. 2000;157:2133–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864–70.

    Article  CAS  PubMed  Google Scholar 

  58. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991;253:49–53.

    Article  CAS  PubMed  Google Scholar 

  59. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989;246:491–4.

    Article  CAS  PubMed  Google Scholar 

  60. Takahashi T, D’Amico D, Chiba I, Buchhagen DL, Minna JD. Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J Clin Invest. 1990;86:363–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990;335:675–9.

    Article  CAS  PubMed  Google Scholar 

  62. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci. 2004;95:197–204.

    Article  CAS  PubMed  Google Scholar 

  63. Yokota J, Nishioka M, Tani M, Kohno T. Genetic alterations responsible for metastatic phenotypes of lung cancer cells. Clin Exp Metastasis. 2003;20:189–93.

    Article  CAS  PubMed  Google Scholar 

  64. Gibbons DL, Lin W, Creighton CJ, Zheng S, Berel D, Yang Y, Raso MG, Liu DD, Wistuba II, Lozano G, Kurie JM. Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS ONE. 2009;4:e5401.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, Lee J, Jung YJ, Kim JO, Yu SB, Kim J, Lee ER, Kang CH, Park IK, Rhee H, Lee SH, Kim JI, Kang JH, Kim YT. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res. 2012;22:2109–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.

    Article  CAS  PubMed  Google Scholar 

  67. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–7.

    Article  CAS  PubMed  Google Scholar 

  68. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.

    Article  CAS  PubMed  Google Scholar 

  69. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol. 2005;32:315–28.

    Article  CAS  PubMed  Google Scholar 

  70. Monnier Y, Farmer P, Bieler G, Imaizumi N, Sengstag T, Alghisi GC, Stehle JC, Ciarloni L, Andrejevic-Blant S, Moeckli R, Mirimanoff RO, Goodman SL, Delorenzi M, Ruegg C. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 2008;68:7323–31.

    Article  CAS  PubMed  Google Scholar 

  71. Sun L, Liu Y, Lin S, Shang J, Liu J, Li J, Yuan S, Zhang L. Early growth response gene-1 and hypoxia-inducible factor-1alpha affect tumor metastasis via regulation of tissue factor. Acta Oncol. 2013;52:842–51.

    Article  CAS  PubMed  Google Scholar 

  72. Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G, Ciardiello F. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol. 2006;208:344–53.

    Article  CAS  PubMed  Google Scholar 

  73. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE, Paz-Ares L, Storkel S, Schumacher KM, von Heydebreck A, Celik I, O’Byrne KJ. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33–42.

    Article  CAS  PubMed  Google Scholar 

  74. Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR, Hunt JD. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev. 1997;6:841–7.

    CAS  PubMed  Google Scholar 

  75. Wislez M, Fujimoto N, Izzo JG, Hanna AE, Cody DD, Langley RR, Tang H, Burdick MD, Sato M, Minna JD, Mao L, Wistuba I, Strieter RM, Kurie JM. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 2006;66:4198–207.

    Article  CAS  PubMed  Google Scholar 

  76. To MD, Wong CE, Karnezis AN, Del Rosario R, Di Lauro R, Balmain A. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet. 2008;40:1240–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Zhou Y, Rideout 3rd WM, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol. 2010;28:71–8.

    Article  CAS  PubMed  Google Scholar 

  78. Musteanu M, Blaas L, Zenz R, Svinka J, Hoffmann T, Grabner B, Schramek D, Kantner HP, Muller M, Kolbe T, Rulicke T, Moriggl R, Kenner L, Stoiber D, Penninger JM, Popper H, Casanova E, Eferl R. A mouse model to identify cooperating signaling pathways in cancer. Nat Methods. 2012;9:897–900.

    Article  CAS  PubMed  Google Scholar 

  79. Geles A, Gruber-Moesenbacher U, Quehenberger F, Manzl C, Al Effah M, Grygar E, Juettner-Smolle F, Popper HH. Pulmonary mucinous adenocarcinomas: architectural patterns in correlation with genetic changes, prognosis and survival. Virchows Arch. 2015;467:675–86.

    Article  CAS  PubMed  Google Scholar 

  80. Rekhtman N, Ang DC, Riely GJ, Ladanyi M, Moreira AL. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol. 2013;26:1307–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, Ji H. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE. 2011;6:e28204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Gao B, Sun Y, Zhang J, Ren Y, Fang R, Han X, Shen L, Liu XY, Pao W, Chen H, Ji H. Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas. J Thorac Oncol. 2010;5:1130–5.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Ren S, Kuang P, Zheng L, Su C, Li J, Li B, Chen X, Wang Y, Kimcurran V, Liu L, Hu Q, Zhang J, Tang L, Zhou C. Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys. 2012;64:155–60.

    Article  CAS  PubMed  Google Scholar 

  84. Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Janne PA. Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer. 2008;99:245–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer. 2012;48:961–73.

    Article  CAS  PubMed  Google Scholar 

  87. Ikeda K, Nomori H, Mori T, Sasaki J, Kobayashi T. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg. 2008;85:1430–2.

    Article  PubMed  Google Scholar 

  88. Zucali PA, Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006;42:2706–14.

    Article  CAS  PubMed  Google Scholar 

  89. Nakao M, Yoshida J, Goto K, Ishii G, Kawase A, Aokage K, Hishida T, Nishimura M, Nagai K. Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol. 2012;7:1563–6.

    Article  PubMed  Google Scholar 

  90. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, Moran L, Mohemmad QK, Anjum R, Wang Y, Narasimhan NI, Dalgarno D, Shakespeare WC, Miret JJ, Clackson T, Rivera VM. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011;78:999–1005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 2012;103:1189–94.

    Article  CAS  PubMed  Google Scholar 

  92. Janne PA, Meyerson M. ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol. 2012;30:878–9.

    Article  CAS  PubMed  Google Scholar 

  93. Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V, Kris MG, Zakowski MF, Rizvi N, Khanin R, Ladanyi M. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res. 2012;18:6599–608.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449–57.

    Article  CAS  PubMed  Google Scholar 

  95. Arai Y, Totoki Y, Takahashi H, Nakamura H, Hama N, Kohno T, Tsuta K, Yoshida A, Asamura H, Mutoh M, Hosoda F, Tsuda H, Shibata T. Mouse model for ROS1-rearranged lung cancer. PLoS ONE. 2013;8:e56010.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol. 2012;7:1625–30.

    Article  CAS  PubMed  Google Scholar 

  98. Komiya T, Thomas A, Khozin S, Rajan A, Wang Y, Giaccone G. Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J Clin Oncol. 2012;30:3425–6. author reply 3426.

    Article  PubMed  Google Scholar 

  99. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol. 2012;7:1086–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res. 2012;22:436–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C, Luo X, Wang L, Li H, Zhang Y, Li F, Lu Y, Lu Q, Xu J, Garfield D, Shen L, Ji H, Pao W, Sun Y, Chen H. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol. 2012;30:4352–9.

    Article  CAS  PubMed  Google Scholar 

  102. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–81.

    Article  CAS  PubMed  Google Scholar 

  103. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104:20932–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med. 2013;368:1685–94.

    Article  CAS  PubMed  Google Scholar 

  105. Zhang YW, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 2013;12:1429–41.

    Article  CAS  PubMed  Google Scholar 

  106. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt Jr JH, Blumenschein Jr GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:4105–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Borczuk AC, Gorenstein L, Walter KL, Assaad AA, Wang L, Powell CA. Non-small-cell lung cancer molecular signatures recapitulate lung developmental pathways. Am J Pathol. 2003;163:1949–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004;112:171–8.

    Article  CAS  PubMed  Google Scholar 

  109. Sengupta N, Seto E. Regulation of histone deacetylase activities. J Cell Biochem. 2004;93:57–67.

    Article  CAS  PubMed  Google Scholar 

  110. Melhuish TA, Gallo CM, Wotton D. TGIF2 interacts with histone deacetylase 1 and represses transcription. J Biol Chem. 2001;276:32109–14.

    Article  CAS  PubMed  Google Scholar 

  111. Beisel C, Imhof A, Greene J, Kremmer E, Sauer F. Histone methylation by the drosophila epigenetic transcriptional regulator Ash1. Nature. 2002;419:857–62.

    Article  CAS  PubMed  Google Scholar 

  112. Soejima H, Joh K, Mukai T. Gene silencing in DNA damage repair. Cell Mol Life Sci. 2004;61:2168–72.

    Article  CAS  PubMed  Google Scholar 

  113. Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol. 2004;82:263–74.

    Article  CAS  PubMed  Google Scholar 

  114. Sasaki H, Moriyama S, Nakashima Y, Kobayashi Y, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer. 2004;46:171–8.

    Article  PubMed  Google Scholar 

  115. Chen MC, Chen CH, Wang JC, Tsai AC, Liou JP, Pan SL, Teng CM. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis. 2013;4:e810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Pal SK, Figlin RA, Reckamp K. Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther. 2010;9:1931–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. An SJ, Chen ZH, Su J, Zhang XC, Zhong WZ, Yang JJ, Zhou Q, Yang XN, Huang L, Guan JL, Nie Q, Yan HH, Mok TS, Wu YL. Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE. 2012;7:e40109.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Moorehead RA, Sanchez OH, Baldwin RM, Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene. 2003;22:853–7.

    Article  CAS  PubMed  Google Scholar 

  119. Gharib TG, Chen G, Huang CC, Misek DE, Iannettoni MD, Hanash SM, Orringer MB, Beer DG. Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas. Clin Lung Cancer. 2004;5:307–12.

    Article  CAS  PubMed  Google Scholar 

  120. Chen Y, Pacyna-Gengelbach M, Ye F, Knosel T, Lund P, Deutschmann N, Schluns K, Kotb WF, Sers C, Yasumoto H, Usui T, Petersen I. Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol. 2007;211:431–8.

    Article  CAS  PubMed  Google Scholar 

  121. Morgillo F, Kim WY, Kim ES, Ciardiello F, Hong WK, Lee HY. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res. 2007;13:2795–803.

    Article  CAS  PubMed  Google Scholar 

  122. Gualberto A, Karp DD. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer. 2009;10:273–80.

    Article  CAS  PubMed  Google Scholar 

  123. Gridelli C, Rossi A, Bareschino MA, Schettino C, Sacco PC, Maione P. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs. 2010;19:631–9.

    Article  CAS  PubMed  Google Scholar 

  124. Hurbin A, Wislez M, Busser B, Antoine M, Tenaud C, Rabbe N, Dufort S, de Fraipont F, Moro-Sibilot D, Cadranel J, Coll JL, Brambilla E. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol. 2011;225:83–95.

    Article  CAS  PubMed  Google Scholar 

  125. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, Moch H, Wagener P, Fischer F, Heynck S, Koker M, Schottle J, Leenders F, Gabler F, Dabow I, Querings S, Heukamp LC, Balke-Want H, Ansen S, Rauh D, Baessmann I, Altmuller J, Wainer Z, Conron M, Wright G, Russell P, Solomon B, Brambilla E, Brambilla C, Lorimier P, Sollberg S, Brustugun OT, Engel-Riedel W, Ludwig C, Petersen I, Sanger J, Clement J, Groen H, Timens W, Sietsma H, Thunnissen E, Smit E, Heideman D, Cappuzzo F, Ligorio C, Damiani S, Hallek M, Beroukhim R, Pao W, Klebl B, Baumann M, Buettner R, Ernestus K, Stoelben E, Wolf J, Nurnberg P, Perner S, Thomas RK. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE. 2011;6:e20351.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res. 2011;71:4920–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan Sr R, Kukral DW, Kamath A, Marathe P, D’Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem. 2008;51:1976–80.

    Article  CAS  PubMed  Google Scholar 

  129. Antoniu SA, Kolb MR. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs. 2010;13:332–45.

    CAS  PubMed  Google Scholar 

  130. Sakamoto H, Tsukaguchi T, Hiroshima S, Kodama T, Kobayashi T, Fukami TA, Oikawa N, Tsukuda T, Ishii N, Aoki Y. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19:679–90.

    Article  CAS  PubMed  Google Scholar 

  131. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013;7:112–20.

    Article  CAS  PubMed  Google Scholar 

  132. Mantripragada K, Khurshid H. Targeting genomic alterations in squamous cell lung cancer. Front Oncol. 2013;3:195.

    Article  PubMed  PubMed Central  Google Scholar 

  133. Li L, Yu H, Wang X, Zeng J, Li D, Lu J, Wang C, Wang J, Wei J, Jiang M, Mo B. Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res. 2013;32:28.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  134. Martinez VD, Thu KL, Vucic EA, Hubaux R, Adonis M, Gil L, MacAulay C, Lam S, Lam WL. Whole-genome sequencing analysis identifies a distinctive mutational spectrum in an arsenic-related lung tumor. J Thorac Oncol. 2013;8:1451–5.

    Article  CAS  PubMed  Google Scholar 

  135. Lee YY, Kim HP, Kang MJ, Cho BK, Han SW, Kim TY, Yi EC. Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp Mol Med. 2013;45:e64.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  136. Politi K, Fan PD, Shen R, Zakowski M, Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis Model Mech. 2010;3:111–9.

    Article  CAS  PubMed  Google Scholar 

  137. Chen Y, Huang Y, Chen J, Wang S, Zhou J. The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS ONE. 2013;8:e71140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  138. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, Morere JF, Khayat D, Spano JP. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res. 2003;23:4885–90.

    CAS  PubMed  Google Scholar 

  140. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–101.

    Article  CAS  PubMed  Google Scholar 

  141. Zhang F, Zhang X, Li M, Chen P, Zhang B, Guo H, Cao W, Wei X, Cao X, Hao X, Zhang N. mTOR complex component rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res. 2010;70:9360–70.

    Article  CAS  PubMed  Google Scholar 

  142. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–68.

    Article  CAS  PubMed  Google Scholar 

  143. Jia P, Jin H, Meador CB, Xia J, Ohashi K, Liu L, Pirazzoli V, Dahlman KB, Politi K, Michor F, Zhao Z, Pao W. Next-generation sequencing of paired tyrosine kinase inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines identifies spectrum of DNA changes associated with drug resistance. Genome Res. 2013;23:1434–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24:2371–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Han AJ, Xiong M, Zong YS. Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am J Clin Pathol. 2000;114:220–6.

    Article  CAS  PubMed  Google Scholar 

  146. Pros E, Lantuejoul S, Sanchez-Verde L, Castillo SD, Bonastre E, Suarez-Gauthier A, Conde E, Cigudosa JC, Lopez-Rios F, Torres-Lanzas J, Castellvi J, Ramon y Cajal S, Brambilla E, Sanchez-Cespedes M. Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. Int J Cancer. 2013;133:898–907.

    Article  CAS  PubMed  Google Scholar 

  147. Han AJ, Xiong M, Gu YY, Lin SX. Lymphoepithelioma-like carcinoma of the lung with a better prognosis. A clinicopathologic study of 32 cases. Am J Clin Pathol. 2001;115:841–50.

    Article  CAS  PubMed  Google Scholar 

  148. Hou M, Morishita Y, Iljima T, Inadome Y, Mase K, Dai Y, Noguchi M. DNA methylation and expression of p16(INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung. Int J Cancer. 1999;84:609–13.

    Article  CAS  PubMed  Google Scholar 

  149. Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene. 2002;21:7421–34.

    Article  CAS  PubMed  Google Scholar 

  150. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, Harada K, Ariyoshi Y, Takahashi T, Sugio K, Brambilla E, Gilcrease M, Minna JD, Gazdar AF. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1:61–7.

    CAS  PubMed  Google Scholar 

  151. Licciulli S, Avila JL, Hanlon L, Troutman S, Cesaroni M, Kota S, Keith B, Simon MC, Pure E, Radtke F, Capobianco AJ, Kissil JL. Notch1 is required for kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res. 2013;73:5974–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Bernheim A, Toujani S, Saulnier P, Robert T, Casiraghi O, Validire P, Temam S, Menard P, Dessen P, Fouret P. High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest. 2008;88:464–73.

    Article  CAS  PubMed  Google Scholar 

  153. McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J. Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009;69:3937–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Zhang L, Mitani Y, Caulin C, Rao PH, Kies MS, Saintigny P, Zhang N, Weber RS, Lippman SM, El-Naggar AK. Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. Am J Pathol. 2013;182:2048–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  155. Rossi G, Mengoli MC, Cavazza A, Nicoli D, Barbareschi M, Cantaloni C, Papotti M, Tironi A, Graziano P, Paci M, Stefani A, Migaldi M, Sartori G, Pelosi G. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014;464:61–8.

    Article  CAS  PubMed  Google Scholar 

  156. Tsao MS, Liu N, Chen JR, Pappas J, Ho J, To C, Viallet J, Park M, Zhu H. Differential expression of met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer. 1998;20:1–16.

    Article  CAS  PubMed  Google Scholar 

  157. Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer. 2012;118:729–39.

    Article  CAS  PubMed  Google Scholar 

  158. Strazisar M, Mlakar V, Rott T, Glavac D. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma. Cancer Invest. 2009;27:407–16.

    Article  CAS  PubMed  Google Scholar 

  159. Mak BC, Yeung RS. The tuberous sclerosis complex genes in tumor development. Cancer Invest. 2004;22:588–603.

    Article  CAS  PubMed  Google Scholar 

  160. Wockel W, Hofler G, Popper HH, Morresi A. Lymphoepithelioma-like carcinoma of the lung. Pathol Res Pract. 1995;191:1170–4.

    Article  CAS  PubMed  Google Scholar 

  161. Chang YL, Wu CT, Shih JY, Lee YC. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol. 2002;26:715–23.

    Article  PubMed  Google Scholar 

  162. Chang YL, Wu CT, Shih JY, Lee YC. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci. 2011;102:282–7.

    Article  CAS  PubMed  Google Scholar 

  163. Uchida K, Kojima A, Morokawa N, Tanabe O, Anzai C, Kawakami M, Eto Y, Yoshimura K. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol. 2002;128:633–40.

    Article  CAS  PubMed  Google Scholar 

  164. Levin NA, Brzoska PM, Warnock ML, Gray JW, Christman MF. Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosom Cancer. 1995;13:175–85.

    Article  CAS  PubMed  Google Scholar 

  165. Schwendel A, Langreck H, Reichel M, Schrock E, Ried T, Dietel M, Petersen I. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int J Cancer. 1997;74:86–93.

    Article  CAS  PubMed  Google Scholar 

  166. Ullmann R, Schwendel A, Klemen H, Wolf G, Petersen I, Popper HH. Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol. 1998;29:1145–9.

    Article  CAS  PubMed  Google Scholar 

  167. Harbour JW, Lai SL, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241:353–7.

    Article  CAS  PubMed  Google Scholar 

  168. Lai SL, Brauch H, Knutsen T, Johnson BE, Nau MM, Mitsudomi T, Tsai CM, Whang-Peng J, Zbar B, Kaye FJ, et al. Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res. 1995;15:225–32.

    CAS  PubMed  Google Scholar 

  169. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol. 2001;28:3–13.

    Article  CAS  PubMed  Google Scholar 

  170. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst. 2001;93:691–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  171. Senderowicz AM, Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. Small-molecule cyclin-dependent kinase modulators frequent loss of fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. Oncogene. 2003;22:6609–20.

    Article  CAS  PubMed  Google Scholar 

  172. Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD, Pollack JR. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene. 2006;25:130–8.

    Article  CAS  PubMed  Google Scholar 

  173. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther. 2002;1:913–22.

    CAS  PubMed  Google Scholar 

  174. Ball DW, Azzoli CG, Baylin SB, Chi D, Dou S, Donis-Keller H, Cumaraswamy A, Borges M, Nelkin BD. Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Int J Cancer. 1993;54:784–92.

    Article  Google Scholar 

  175. Westerman BA, Breuer RH, Poutsma A, Chhatta A, Noorduyn LA, Koolen MG, Postmus PE, Blankenstein MA, Oudejans CB. Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors. Int J Biol Markers. 2007;22:114–23.

    CAS  PubMed  Google Scholar 

  176. Miki M, Ball DW, Linnoila RI. Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer. 2012;75:58–65.

    Article  PubMed  Google Scholar 

  177. Osada H, Tomida S, Yatabe Y, Tatematsu Y, Takeuchi T, Murakami H, Kondo Y, Sekido Y, Takahashi T. Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res. 2008;68:1647–55.

    Article  CAS  PubMed  Google Scholar 

  178. Linnoila RI, Zhao B, DeMayo JL, Nelkin BD, Baylin SB, DeMayo FJ, Ball DW. Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res. 2000;60:4005–9.

    CAS  PubMed  Google Scholar 

  179. Hiroshima K, Iyoda A, Shibuya K, Haga Y, Toyozaki T, Iizasa T, Nakayama T, Fujisawa T, Ohwada H. Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer. 2004;100:1190–8.

    Article  CAS  PubMed  Google Scholar 

  180. Ullmann R, Petzmann S, Sharma A, Cagle PT, Popper HH. Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol. 2001;32:1059–63.

    Article  CAS  PubMed  Google Scholar 

  181. Nasgashio R, Sato Y, Matsumoto T, Kageyama T, Hattori M, Iyoda A, Satoh Y, Ryuge S, Masuda N, Jiang SX, Saegusa M. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung. Lung Cancer. 2011;74:405–10.

    Article  PubMed  Google Scholar 

  182. Petzmann S, Ullmann R, Halbwedl I, Popper HH. Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Virchows Arch. 2004;445:151–9.

    Article  CAS  PubMed  Google Scholar 

  183. Macarenco RS, Uphoff TS, Gilmer HF, Jenkins RB, Thibodeau SN, Lewis JE, Molina JR, Yang P, Aubry MC. Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol. 2008;21:1168–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  184. Han SW, Kim HP, Jeon YK, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Heo DS, Bang YJ, Kim TY. Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer. 2008;61:30–4.

    Article  PubMed  Google Scholar 

  185. O’Neill ID. Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene. Lung Cancer. 2009;64:129–30.

    Article  PubMed  Google Scholar 

  186. Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN. Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther. 2006;5:2696–705.

    Article  CAS  PubMed  Google Scholar 

  187. Aubry MC, Heinrich MC, Molina J, Lewis JE, Yang P, Cassivi SD, Corless CL. Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer. 2007;110:2507–10.

    Article  PubMed  Google Scholar 

  188. Dahse R, Driemel O, Schwarz S, Kromeyer-Hauschild K, Berndt A, Kosmehl H. KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol. 2009;45:826–9.

    Article  CAS  PubMed  Google Scholar 

  189. Hu JA, Li Y, Fang J. Effect of ERK inhibitor on pulmonary metastasis of inoculated human adenoid cystic carcinoma cells in nude mice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:117–23.

    Article  PubMed  Google Scholar 

  190. Dammrich DJ, Santos ES, Raez LE. Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep. 2011;5:483.

    Article  PubMed  PubMed Central  Google Scholar 

  191. Chau NG, Hotte SJ, Chen EX, Chin SF, Turner S, Wang L, Siu LL. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23:1562–70.

    Article  CAS  PubMed  Google Scholar 

  192. Persson M, Andren Y, Moskaluk CA, Frierson Jr HF, Cooke SL, Futreal PA, Kling T, Nelander S, Nordkvist A, Persson F, Stenman G. Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosom Cancer. 2012;51:805–17.

    Article  CAS  PubMed  Google Scholar 

  193. Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, Drobnjak M, Leversha MA, Rice CE, Singh B, Iyer NG, Leemans CR, Bloemena E, Ferris RL, Seethala RR, Gross BE, Liang Y, Sinha R, Peng L, Raphael BJ, Turcan S, Gong Y, Schultz N, Kim S, Chiosea S, Shah JP, Sander C, Lee W, Chan TA. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45:791–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  194. Stephens PJ, Davies HR, Mitani Y, Van Loo P, Shlien A, Tarpey PS, Papaemmanuil E, Cheverton A, Bignell GR, Butler AP, Gamble J, Gamble S, Hardy C, Hinton J, Jia M, Jayakumar A, Jones D, Latimer C, McLaren S, McBride DJ, Menzies A, Mudie L, Maddison M, Raine K, Nik-Zainal S, O’Meara S, Teague JW, Varela I, Wedge DC, Whitmore I, Lippman SM, McDermott U, Stratton MR, Campbell PJ, El-Naggar AK, Futreal PA. Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest. 2013;123:2965–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  195. Pelosi G, Fraggetta F, Nappi O, Pastorino U, Maisonneuve P, Pasini F, Iannucci A, Solli P, Musavinasab HS, De Manzoni G, Terzi A, Viale G. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27:1203–15.

    Article  PubMed  Google Scholar 

  196. Blaukovitsch M, Halbwedl I, Kothmaier H, Gogg-Kammerer M, Popper HH. Sarcomatoid carcinomas of the lung – are these histogenetically heterogeneous tumors? Virchows Arch. 2006;449:455–61.

    Article  CAS  PubMed  Google Scholar 

  197. Italiano A, Cortot AB, Ilie M, Martel-Planche G, Fabas T, Pop D, Mouroux J, Hofman V, Hofman P, Pedeutour F. EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 2009;125:2479–82.

    Article  CAS  PubMed  Google Scholar 

  198. Henske EP, McCormack FX. Lymphangioleiomyomatosis – a wolf in sheep’s clothing. J Clin Invest. 2012;122:3807–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  199. Burger JA, Stewart DJ, Wald O, Peled A. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev Anticancer Ther. 2011;11:621–30.

    Article  CAS  PubMed  Google Scholar 

  200. Fan TW, Lane AN, Higashi RM, Farag MA, Gao H, Bousamra M, Miller DM. Altered regulation of metabolic pathways in human lung cancer discerned by (13)C stable isotope-resolved metabolomics (SIRM). Mol Cancer. 2009;8:41.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  201. Malchers F, Dietlein F, Schottle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich R, Reinhardt HC, Ringeisen F, Buttner R, Heukamp LC, Wolf J, Thomas RK. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov. 2014;4:246–57.

    Google Scholar 

  202. Massion PP, Taflan PM, Jamshedur Rahman SM, Yildiz P, Shyr Y, Edgerton ME, Westfall MD, Roberts JR, Pietenpol JA, Carbone DP, Gonzalez AL. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113–21.

    CAS  PubMed  Google Scholar 

  203. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL. Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med. 2004;170:1088–94.

    Article  PubMed  Google Scholar 

  204. Tang X, Liu D, Shishodia S, Ozburn N, Behrens C, Lee JJ, Hong WK, Aggarwal BB, Wistuba II. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer. 2006;107:2637–46.

    Article  CAS  PubMed  Google Scholar 

  205. Shen J, Behrens C, Wistuba II, Feng L, Lee JJ, Hong WK, Lotan R. Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res. 2006;66:11194–206.

    Article  CAS  PubMed  Google Scholar 

  206. Ullmann R, Bongiovanni M, Halbwedl I, Fraire AE, Cagle PT, Mori M, Papotti M, Popper HH. Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? J Pathol. 2003;201:371–6.

    Article  CAS  PubMed  Google Scholar 

  207. Mori M, Rao SK, Popper HH, Cagle PT, Fraire AE. Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol. 2001;14:72–84.

    Article  CAS  PubMed  Google Scholar 

  208. Westra WH, Baas IO, Hruban RH, Askin FB, Wilson K, Offerhaus GJ, Slebos RJ. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996;56:2224–8.

    CAS  PubMed  Google Scholar 

  209. Cooper CA, Carby FA, Bubb VJ, Lamb D, Kerr KM, Wyllie AH. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J Pathol. 1997;181:401–4.

    Article  CAS  PubMed  Google Scholar 

  210. Suzuki K, Ogura T, Yokose T, Nagai K, Mukai K, Kodama T, Nishiwaki Y, Esumi H. Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer. 1998;79:384–9.

    Article  CAS  PubMed  Google Scholar 

  211. Takamochi K, Ogura T, Suzuki K, Kawasaki H, Kurashima Y, Yokose T, Ochiai A, Nagai K, Nishiwaki Y, Esumi H. Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol. 2001;159:1941–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  212. Haneda H, Sasaki H, Shimizu S, Endo K, Suzuki E, Yukiue H, Kobayashi Y, Yano M, Fujii Y. Epidermal growth factor receptor gene mutation defines distinct subsets among small adenocarcinomas of the lung. Lung Cancer. 2006;52:47–52.

    Article  PubMed  Google Scholar 

  213. Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol. 2005;58:1076–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. Sakamoto H, Shimizu J, Horio Y, Ueda R, Takahashi T, Mitsudomi T, Yatabe Y. Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol. 2007;212:287–94.

    Article  CAS  PubMed  Google Scholar 

  215. Ullmann R, Bongiovanni M, Halbwedl I, Petzmann S, Gogg-Kammerer M, Sapino A, Papotti M, Bussolati G, Popper HH. Bronchiolar columnar cell dysplasia – genetic analysis of a novel preneoplastic lesion of peripheral lung. Virchows Arch. 2003;442:429–36.

    PubMed  Google Scholar 

  216. Casiraghi M, Travaini LL, Maisonneuve P, Tessitore A, Brambilla D, Agoglia BG, Guarize J, Spaggiari L. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria? Eur J Cardiothorac Surg. 2011;39:e38–43.

    Article  PubMed  Google Scholar 

  217. Stacher E, Ullmann R, Halbwedl I, Gogg-Kammerer M, Boccon-Gibod L, Nicholson AG, Sheppard MN, Carvalho L, Franca MT, Macsweeney F, Morresi-Hauf A, Popper HH. Atypical goblet cell hyperplasia in congenital cystic adenomatoid malformation as a possible preneoplasia for pulmonary adenocarcinoma in childhood: a genetic analysis. Hum Pathol. 2004;35:565–70.

    Article  CAS  PubMed  Google Scholar 

  218. Sartelet H, Decaussin M, Devouassoux G, Nawrocki-Raby B, Brichon PY, Brambilla C, Brambilla E. Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 [Flt-1] and VEGF-R2 [KDR/Flk-1]) in tumorlets and in neuroendocrine cell hyperplasia of the lung. Hum Pathol. 2004;35:1210–7.

    Article  CAS  PubMed  Google Scholar 

  219. Zynger DL, Dimov ND, Ho LC, Laskin WB, Yeldandi AV. Differential expression of neural-cadherin in pulmonary epithelial tumours. Histopathology. 2008;52:348–54.

    Article  CAS  PubMed  Google Scholar 

  220. Popper HH, Wirnsberger G, Juttner-Smolle FM, Pongratz MG, Sommersgutter M. The predictive value of human papilloma virus (HPV) typing in the prognosis of bronchial squamous cell papillomas. Histopathology. 1992;21:323–30.

    Article  CAS  PubMed  Google Scholar 

  221. Popper HH, El-Shabrawi Y, Wockel W, Hofler G, Kenner L, Juttner-Smolle FM, Pongratz MG. Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: comparison of in situ hybridization and the polymerase chain reaction. Hum Pathol. 1994;25:1191–7.

    Article  CAS  PubMed  Google Scholar 

  222. Solinas-Toldo S, Durst M, Lichter P. Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proc Natl Acad Sci U S A. 1997;94:3854–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  223. Lele SM, Pou AM, Ventura K, Gatalica Z, Payne D. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med. 2002;126:1184–8.

    CAS  PubMed  Google Scholar 

  224. Dishop MK, McKay EM, Kreiger PA, Priest JR, Williams GM, Langston C, Jarzembowski J, Suchi M, Dehner LP, Hill DA. Fetal lung interstitial tumor (FLIT): a proposed newly recognized lung tumor of infancy to be differentiated from cystic pleuropulmonary blastoma and other developmental pulmonary lesions. Am J Surg Pathol. 2010;34:1762–72.

    Article  PubMed  Google Scholar 

  225. Hosaka N, Sasaki T, Adachi K, Sato T, Tanaka T, Miura Y, Sawai T, Toki J, Hisha H, Okamura A, Takasu K, Ikehara S. Pulmonary sclerosing hemangioma associated with familial adenomatous polyposis. Hum Pathol. 2004;35:764–8.

    Article  PubMed  Google Scholar 

  226. Wu CT, Chang YL, Lee YC. Expression of the estrogen receptor beta in 37 surgically treated pulmonary sclerosing hemangiomas in comparison with non-small cell lung carcinomas. Hum Pathol. 2005;36:1108–12.

    Article  CAS  PubMed  Google Scholar 

  227. Sartori G, Bettelli S, Schirosi L, Bigiani N, Maiorana A, Cavazza A, Rossi G. Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. Am J Surg Pathol. 2007;31:1512–20.

    Article  PubMed  Google Scholar 

  228. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J, Henske EP. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene. 2002;21:8470–6.

    Article  CAS  PubMed  Google Scholar 

  229. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res. 2007;67:9878–86.

    Article  CAS  PubMed  Google Scholar 

  230. Popper HH, Juettner-Smolle FM, Pongratz MG. Micronodular hyperplasia of type II pneumocytes – a new lung lesion associated with tuberous sclerosis. Histopathology. 1991;18:347–54.

    Article  CAS  PubMed  Google Scholar 

  231. Muir TE, Leslie KO, Popper H, Kitaichi M, Gagne E, Emelin JK, Vinters HV, Colby TV. Micronodular pneumocyte hyperplasia. Am J Surg Pathol. 1998;22:465–72.

    Article  CAS  PubMed  Google Scholar 

  232. Maruyama H, Ohbayashi C, Hino O, Tsutsumi M, Konishi Y. Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2. Pathol Int. 2001;51:585–94.

    Article  CAS  PubMed  Google Scholar 

  233. Carrington CB, Cugell DW, Gaensler EA, Marks A, Redding RA, Schaaf JT, Tomasian A. Lymphangioleiomyomatosis. Physiologic-pathologic-radiologic correlations. Am Rev Respir Dis. 1977;116:977–95.

    CAS  PubMed  Google Scholar 

  234. Nine JS, Yousem SA, Paradis IL, Keenan R, Griffith BP. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant. 1994;13:714–9.

    CAS  PubMed  Google Scholar 

  235. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol. 1997;28:1420–3.

    Article  CAS  PubMed  Google Scholar 

  236. Bittmann I, Rolf B, Amann G, Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol. 2003;34:95–8.

    Article  PubMed  Google Scholar 

  237. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy Jr JP, Wang JA, Kumaki F, Darling T, Moss J. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004;101:17462–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  238. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000;97:6085–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  239. Sampson JR. TSC1 and TSC2: genes that are mutated in the human genetic disorder tuberous sclerosis. Biochem Soc Trans. 2003;31:592–6.

    Article  CAS  PubMed  Google Scholar 

  240. Sietsema KE, McCormack FX. Lymphangioleiomyomatosis: insights about, and from, a rare disease. Am J Respir Crit Care Med. 2003;168:1405–6.

    Article  PubMed  Google Scholar 

  241. Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–81.

    Article  CAS  PubMed  Google Scholar 

  242. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch 3rd JP, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–606.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  243. Harris GC, McCulloch TA, Perks G, Fisher C. Malignant perivascular epithelioid cell tumour (“PEComa”) of soft tissue: a unique case. Am J Surg Pathol. 2004;28:1655–8.

    Article  PubMed  Google Scholar 

  244. Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Arch. 2008;452:119–32.

    Article  PubMed  Google Scholar 

  245. Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005;24:7475–81.

    Article  CAS  PubMed  Google Scholar 

  246. Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario Jr FJ, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE. 2011;6:e23379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  247. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:5659–67.

    Article  CAS  PubMed  Google Scholar 

  248. Hachitanda Y, Aoyama C, Sato JK, Shimada H. Pleuropulmonary blastoma in childhood. A tumor of divergent differentiation. Am J Surg Pathol. 1993;17:382–91.

    Article  CAS  PubMed  Google Scholar 

  249. Dehner LP. Pleuropulmonary blastoma is THE pulmonary blastoma of childhood. Semin Diagn Pathol. 1994;11:144–51.

    CAS  PubMed  Google Scholar 

  250. Novak R, Dasu S, Agamanolis D, Herold W, Malone J, Waterson J. Trisomy 8 is a characteristic finding in pleuropulmonary blastoma. Pediatr Pathol Lab Med. 1997;17:99–103.

    Article  CAS  PubMed  Google Scholar 

  251. Barnard M, Bayani J, Grant R, Teshima I, Thorner P, Squire J. Use of multicolor spectral karyotyping in genetic analysis of pleuropulmonary blastoma. Pediatr Dev Pathol. 2000;3:479–86.

    Article  CAS  PubMed  Google Scholar 

  252. Vargas SO, Nose V, Fletcher JA, Perez-Atayde AR. Gains of chromosome 8 are confined to mesenchymal components in pleuropulmonary blastoma. Pediatr Dev Pathol. 2001;4:434–45.

    Article  CAS  PubMed  Google Scholar 

  253. Roque L, Rodrigues R, Martins C, Ribeiro C, Ribeiro MJ, Martins AG, Oliveira P, Fonseca I. Comparative genomic hybridization analysis of a pleuropulmonary blastoma. Cancer Genet Cytogenet. 2004;149: 58–62.

    Article  PubMed  Google Scholar 

  254. Kusafuka T, Kuroda S, Inoue M, Ara T, Yoneda A, Oue T, Udatsu Y, Osugi Y, Okada A. P53 gene mutations in pleuropulmonary blastomas. Pediatr Hematol Oncol. 2002;19:117–28.

    Article  CAS  PubMed  Google Scholar 

  255. Yang P, Hasegawa T, Hirose T, Fukumoto T, Uyama T, Monden Y, Sano T. Pleuropulmonary blastoma: fluorescence in situ hybridization analysis indicating two PPBs were confirmed to harbor p53 mutations. One was a Val to Leu substitution at codon 173, and another was a ArgArg to TrpCys substitution at codons 282 and 283. In each tumor, only the mutated allele was detected, suggesting inactivation of p53. Am J Surg Pathol. 1997;21:854–9.

    Article  CAS  PubMed  Google Scholar 

  256. Slade I, Bacchelli C, Davies H, Murray A, Abbaszadeh F, Hanks S, Barfoot R, Burke A, Chisholm J, Hewitt M, Jenkinson H, King D, Morland B, Pizer B, Prescott K, Saggar A, Side L, Traunecker H, Vaidya S, Ward P, Futreal PA, Vujanic G, Nicholson AG, Sebire N, Turnbull C, Priest JR, Pritchard-Jones K, Houlston R, Stiller C, Stratton MR, Douglas J, Rahman N. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet. 2011;48:273–8.

    Article  CAS  PubMed  Google Scholar 

  257. Alobeid B, Beneck D, Sreekantaiah C, Abbi RK, Slim MS. Congenital pulmonary myofibroblastic tumor: a case report with cytogenetic analysis and review of the literature. Am J Surg Pathol. 1997;21:610–4.

    Article  CAS  PubMed  Google Scholar 

  258. McGinnis M, Jacobs G, El-Naggar A, Redline RW. Congenital peribronchial myofibroblastic tumor (so-called “congenital leiomyosarcoma”). A distinct neonatal lung lesion associated with nonimmune hydrops fetalis. Mod Pathol. 1993;6:487–92.

    CAS  PubMed  Google Scholar 

  259. Schneider BF, Lovell MA, Golden WL. Cytogenetic abnormalities in primary bronchopulmonary leiomyosarcoma of childhood. Cancer Genet Cytogenet. 1998;105:145–51.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, Medical University Graz, Graz, Austria

    Helmut Popper

Authors
  1. Helmut Popper
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Popper, H. (2017). Molecular Pathology of Lung Tumors. In: Pathology of Lung Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-50491-8_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-50491-8_19

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-50489-5

  • Online ISBN: 978-3-662-50491-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation